Prosight Management Trims BridgeBio Pharma Stake

Institutional investor sells over 200,000 shares of biotech firm

Mar. 14, 2026 at 11:08am

Got story updates? Submit your updates here. ›

Prosight Management LP, an institutional investor, has trimmed its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by selling 208,187 shares during the third quarter. The firm now owns 264,500 shares of the biopharmaceutical company, accounting for approximately 0.14% of BridgeBio Pharma's outstanding stock.

Why it matters

The sale by Prosight Management represents a significant reduction in its stake in BridgeBio Pharma, a clinical-stage biotech firm focused on developing treatments for genetic diseases and cancers. This transaction provides insight into the investment decisions of institutional investors and could signal a shift in sentiment around BridgeBio Pharma's prospects.

The details

According to a 13F filing with the Securities and Exchange Commission, Prosight Management LP sold 208,187 shares of BridgeBio Pharma during the third quarter, reducing its position by 44%. The firm now holds 264,500 shares, worth approximately $13.7 million at the end of the reporting period.

  • Prosight Management LP sold the shares during the third quarter of 2025.

The players

Prosight Management LP

An institutional investor that has reduced its stake in BridgeBio Pharma.

BridgeBio Pharma, Inc.

A clinical-stage biopharmaceutical company focused on developing treatments for genetic diseases and cancers.

Got photos? Submit your photos here. ›

The takeaway

The sale by Prosight Management highlights the volatility and uncertainty surrounding the biotech sector, as institutional investors adjust their portfolios in response to changing market conditions and company performance.